Anti-hepatitis B ribozyme - Ribozyme Pharmaceuticals

Drug Profile

Anti-hepatitis B ribozyme - Ribozyme Pharmaceuticals

Alternative Names: HepBzyme

Latest Information Update: 08 Jan 2008

Price : $50

At a glance

  • Originator Sirna Therapeutics
  • Class
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 13 Nov 2002 Suspended - Phase-I for Hepatitis B in USA (SC)
  • 21 Nov 2001 Preclinical data have been added to the Viral Infections antimicrobial activity section
  • 09 Mar 2001 Phase-I clinical trials for Hepatitis B in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top